{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:06:59Z","timestamp":1785575219362,"version":"3.56.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Thrombocytopenia can occur when using an Impella percutaneous ventricular assist device (pVAD), and heparin-induced thrombocytopenia (HIT) is often suspected. Data on heparin- and anticoagulant-free purge solutions in these devices are limited. Previous case reports have described argatroban-based purge solutions, both with and without systemic argatroban, at varying concentrations in patients with known or suspected HIT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>A 33-year-old male was transferred to our institution and emergently initiated on life support with venoarterial extracorporeal membrane oxygenation (ECMO), an Impella pVAD, and continuous venovenous hemofiltration to receive an urgent aortic valve replacement. Over the next several days, the patient\u2019s platelet count declined with a nadir of 17 \u00d7 103\/\u03bcL on hospital day 13. The patient\u2019s 4T score for probability of HIT was calculated as 4. All heparin products were discontinued on hospital day 15, and the patient was initiated on systemic infusion with argatroban 1,000 \u03bcg\/mL at a rate of 0.2 \u03bcg\/kg\/min with a purge solution of argatroban 0.05 mg\/mL. The systemic infusion remained at a rate of 0.2 \u03bcg\/kg\/min, and the total argatroban dose was, on average, less than 0.25 \u03bcg\/kg\/min. On hospital day 21, the patient was transferred to another institution.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Systemic infusion and a purge solution with argatroban were used in a patient with an Impella pVAD with multisystem organ dysfunction and suspected HIT. The patient achieved therapeutic activated partial thromboplastin times without adjustment of the systemic argatroban infusion and did not experience bleeding or thrombosis. Further studies concerning the safety and effectiveness of argatroban-based purge solutions in patients with pVADs are needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxab331","type":"journal-article","created":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T12:00:50Z","timestamp":1628942450000},"page":"e8-e13","source":"Crossref","is-referenced-by-count":4,"title":["Use of an argatroban systemic infusion and purge solution in a patient with a percutaneous ventricular assist device with suspected heparin-induced thrombocytopenia"],"prefix":"10.1093","volume":"79","author":[{"given":"Ashley N","family":"Shtoyko","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Upstate University Hospital, Syracuse, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Upstate University Hospital, Syracuse, NY"},{"name":"Upstate Pharmacy Services Translational Research Team (UPSTART), Syracuse, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M","family":"Cwikla","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Upstate University Hospital, Syracuse, NY"},{"name":"Upstate Pharmacy Services Translational Research Team (UPSTART), Syracuse, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Darko","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Upstate University Hospital, Syracuse, NY"},{"name":"Department of Medicine, Upstate Medical University, Syracuse, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G Randall","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Surgery, Upstate Medical University, Syracuse, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W","family":"Seabury","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Upstate University Hospital, Syracuse, NY"},{"name":"Department of Medicine, Upstate Medical University, Syracuse, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,14]]},"reference":[{"issue":"5","key":"2021121515421025400_CIT0001","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MAT.0000000000001039","article-title":"Venoarterial extracorporeal membrane oxygenation with concomitant Impella versus venoarterial extracorporeal membrane oxygenation for cardiogenic shock","volume":"66","author":"Vallabhajosyula","year":"2020","journal-title":"ASAIO J."},{"issue":"10","key":"2021121515421025400_CIT0002","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/phar.1995","article-title":"Pharmacologic considerations in the management of patients receiving left ventricular percutaneous mechanical circulatory support","volume":"37","author":"Allender","year":"2017","journal-title":"Pharmacotherapy."},{"issue":"22","key":"2021121515421025400_CIT0003","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv."},{"issue":"2","key":"2021121515421025400_CIT0004","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11239-019-01837-6","article-title":"Management of anticoagulation with Impella percutaneous ventricular assist devices and review of new literature","volume":"48","author":"Succar","year":"2019","journal-title":"J Thromb Thrombolysis."},{"key":"2021121515421025400_CIT0005","volume-title":"Impella Ventricular Support Systems for Use During Cardiogenic Shock and High-Risk PCI. Instructions for Use and Clinical Reference Manual","author":"Abiomed, Inc","year":"2020"},{"key":"2021121515421025400_CIT0006","doi-asserted-by":"crossref","first-page":"3791307","DOI":"10.1155\/2019\/3791307","article-title":"Survey of anticoagulation practices with the Impella percutaneous ventricular assist device at high-volume centers","volume":"2019","author":"Reed","year":"2019","journal-title":"J Interv Cardiol."},{"key":"2021121515421025400_CIT0007","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.2146\/ajhp160212","article-title":"Use of an argatroban-based purge solution in a percutaneous ventricular assist device","volume":"74","author":"Laliberte","year":"2017","journal-title":"Am J Health-Syst Pharm."},{"issue":"5","key":"2021121515421025400_CIT0008","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1177\/0897190017727191","article-title":"Anticoagulation of percutaneous ventricular assist device using argatroban-based purge solution: a case series","volume":"31","author":"Blum","year":"2018","journal-title":"J Pharm Pract."},{"issue":"4","key":"2021121515421025400_CIT0009","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0018578719888905","article-title":"Therapeutic anticoagulation with an ultra-low concentration argatroban-based purge solution for percutaneous ventricular assist device in patient with heparin-induced thrombocytopenia","volume":"56","author":"Newsome","year":"2021","journal-title":"Hosp Pharm."},{"issue":"3","key":"2021121515421025400_CIT0010","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/cc9024","article-title":"Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study","volume":"14","author":"Saugel","year":"2010","journal-title":"Crit Care."},{"key":"2021121515421025400_CIT0011","volume-title":"Package insert","author":"Argatroban","year":"2019"},{"issue":"21","key":"2021121515421025400_CIT0012","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2146\/ajhp100016","article-title":"Extended use of a percutaneous left-ventricular assist device without a heparin-based purge solution","volume":"67","author":"Jennings","year":"2010","journal-title":"Am J Health-Syst Pharm."},{"issue":"5","key":"2021121515421025400_CIT0013","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/0391398820964810","article-title":"Anticoagulation with temporary Impella device in patients with heparin-induced thrombocytopenia: a case series","volume":"44","author":"Hohlfelder","year":"2021","journal-title":"Int J Artif Organs."},{"issue":"9","key":"2021121515421025400_CIT0014","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1097\/MAT.0000000000001126","article-title":"Anticoagulation of Impella with a bivalirudin purge solution","volume":"66","author":"Szymanski","year":"2020","journal-title":"ASAIO J."},{"issue":"4","key":"2021121515421025400_CIT0015","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1177\/0897190020930530","article-title":"Use of systemic bivalirudin and an anticoagulant-free purge solution in a percutaneous left ventricular assist device in a patient with heparin-induced thrombocytopenia","volume":"34","author":"Kazmi","year":"2021","journal-title":"J Pharm Pract."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxab331\/40076594\/zxab331.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/79\/1\/e8\/41772174\/zxab331.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/79\/1\/e8\/41772174\/zxab331.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T15:44:07Z","timestamp":1639583047000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/79\/1\/e8\/6352392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,14]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,8,14]]},"published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxab331","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,8,14]]}}}